{"nctId":"NCT02082769","briefTitle":"Safety and Efficacy of Oral Febuxostat in Subjects With Gout","startDateStruct":{"date":"2011-07"},"conditions":["Gout"],"count":504,"armGroups":[{"label":"Febuxostat 40 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Febuxostat"]},{"label":"Febuxostat 80 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Febuxostat"]},{"label":"Allopurinol 100mg QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Allopurinol"]}],"interventions":[{"name":"Febuxostat","otherNames":[]},{"name":"Allopurinol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hyperuricemia (serum urate ≥8.0 mg/dL) and gout by Chinese Rheumatism Association Criteria;\n* Renal function defined as a serum creatinine level of \\< 2.0 mg/dL and creatinine clearance of \\> 20 milliliters per minute (mL/min) by Cockcroft and Gault formula;\n* No gout flare 2 weeks beforehand during 2-week screening period.\n\nExclusion Criteria:\n\n* Pregnancy or lactation;\n* Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine, thiazide diuretics, or medications containing aspirin (\\>325 mg) or other salicylates;\n* Body Mass Index (BMI) \\>50 kilogram per meter²(kg/m²);\n* A history of active liver disease, or hepatic dysfunction;\n* A history of bronchial asthma;\n* A history of renal calculi or thyroid disease;\n* Secondary gout Joint diseases induced by rheumatoid arthritis, psoriatic arthritis and bone tumor;\n* Intolerance to allopurinol and Ibuprofen;\n* Alcohol intake of ≥ 14 drinks/week;\n* Clinically significant medical condition.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"33.5","spread":null},{"groupId":"OG002","value":"17.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"58.9","spread":null},{"groupId":"OG002","value":"34.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Absolute Change in the Serum Urate Level at the Final Visit Relative to Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182.2","spread":"115.6"},{"groupId":"OG001","value":"216.0","spread":"137.2"},{"groupId":"OG002","value":"170.4","spread":"132.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":168},"commonTop":["Liver function test abnormalities","Others","Renal function test abnormalities","Abnormal urine protein","Drug allergy"]}}}